Fumaric Acid
7 benefits mapped to clinical evidence across supplements.
Benefit Evidence
Psoriasis improvement +50%
GI side effects common
PASI-76% with calcipotriol
Skin improvement, ~50%
T-cell shift, no morphology
DLQI -5.9, PASI75 37.5%
Psoriasis improvement +50%
GI side effects common
PASI-76% with calcipotriol
Research sources
Skin appearance (10)
- Efficacy and safety of fumaric acid esters in young patients aged 10-17 years with moderate-to-severe plaque psoriasis: a randomized, double-blinded, placebo-controlled trial
PubMed ID: 33332574
Pediatric RCT showed substantial PASI75 and PGA improvements, consistent with clearer skin.
- Fumaric acid therapy in psoriasis: a double-blind comparison between fumaric acid compound therapy and monotherapy with dimethylfumaric acid ester
PubMed ID: 2394301
Psoriasis trials report marked clinical improvement, which implies improved skin clarity.
- [Fumaric acid therapy in psoriasis; a double-blind, placebo-controlled study]
PubMed ID: 2263264
Placebo-controlled benefit in psoriasis supports improved skin appearance.
- Antipsoriatic effect of fumaric acid derivatives. Results of a multicenter double-blind study in 100 patients
PubMed ID: 8188891
Multicenter RCT showed superiority over placebo for skin outcomes.
- Topical calcipotriol plus oral fumaric acid is more effective and faster acting than oral fumaric acid monotherapy in the treatment of severe chronic plaque psoriasis vulgaris
PubMed ID: 12145434
Combination therapy with calcipotriol produced substantially greater PASI improvements (better skin clarity).
- Long-term safety and effectiveness of high-dose dimethylfumarate in the treatment of moderate to severe psoriasis: a prospective single-blinded follow-up study
PubMed ID: 26088405
High-dose DMF improved psoriasis over long-term follow-up.
- Efficacy and safety of LAS41008 (dimethyl fumarate) in adults with moderate-to-severe chronic plaque psoriasis: a randomized, double-blind, Fumaderm(®) - and placebo-controlled trial (BRIDGE)
PubMed ID: 27515097
Phase III DMF results show clinically meaningful skin clearance (PASI improvements).
- Fumaric acid esters in combination with a 6-week course of narrowband ultraviolet B provides an accelerated response compared with fumaric acid esters monotherapy in patients with moderate-to-severe plaque psoriasis: a randomized prospective clinical study
PubMed ID: 29114862
Adding NB-UVB to FAE produced faster and greater skin improvement.
- Quality of life outcomes in adults with moderate-to-severe plaque psoriasis treated with dimethylfumarate (DMF): a post hoc analysis of the BRIDGE study
PubMed ID: 31465585
DMF significantly improved PASI and DLQI, indicating better skin clarity in many patients.
- Dimethyl fumarate is efficacious in severe plaque psoriasis : Post hoc analysis from the BRIDGE trial in Austria
PubMed ID: 31591676
Severe subgroup saw improved PGA (clear/almost clear) with DMF versus placebo.
Skin soothing (10)
- Efficacy and safety of LAS41008 (dimethyl fumarate) in adults with moderate-to-severe chronic plaque psoriasis: a randomized, double-blind, Fumaderm(®) - and placebo-controlled trial (BRIDGE)
PubMed ID: 27515097
Phase III trial: oral DMF significantly improved moderate-to-severe plaque psoriasis vs placebo.
- Long-term safety and effectiveness of high-dose dimethylfumarate in the treatment of moderate to severe psoriasis: a prospective single-blinded follow-up study
PubMed ID: 26088405
Long-term DMF therapy reduced psoriasis severity in many patients.
- Topical calcipotriol plus oral fumaric acid is more effective and faster acting than oral fumaric acid monotherapy in the treatment of severe chronic plaque psoriasis vulgaris
PubMed ID: 12145434
Large RCT: adding topical calcipotriol to FAEs produced substantially greater and faster psoriasis improvement.
- Antipsoriatic effect of fumaric acid derivatives. Results of a multicenter double-blind study in 100 patients
PubMed ID: 8188891
Large randomized trial demonstrated efficacy of fumaric acid derivatives for psoriasis.
- [Fumaric acid therapy in psoriasis; a double-blind, placebo-controlled study]
PubMed ID: 2263264
Placebo-controlled study showed significant psoriasis benefit from fumarate-containing tablets.
- Fumaric acid therapy in psoriasis: a double-blind comparison between fumaric acid compound therapy and monotherapy with dimethylfumaric acid ester
PubMed ID: 2394301
Randomized trial: fumaric acid esters produced marked psoriasis improvement in many patients.
- Efficacy and safety of fumaric acid esters in young patients aged 10-17 years with moderate-to-severe plaque psoriasis: a randomized, double-blinded, placebo-controlled trial
PubMed ID: 33332574
Pediatric RCT produced substantial PASI75 improvement versus placebo, indicating fewer flares.
- Dimethyl fumarate is efficacious in severe plaque psoriasis : Post hoc analysis from the BRIDGE trial in Austria
PubMed ID: 31591676
Severe‑patient subgroup showed improved skin clearance and QoL with DMF versus placebo.
- Quality of life outcomes in adults with moderate-to-severe plaque psoriasis treated with dimethylfumarate (DMF): a post hoc analysis of the BRIDGE study
PubMed ID: 31465585
Large randomized trial showed clinically meaningful improvement in skin disease (PASI and DLQI) with DMF.
- Fumaric acid esters in combination with a 6-week course of narrowband ultraviolet B provides an accelerated response compared with fumaric acid esters monotherapy in patients with moderate-to-severe plaque psoriasis: a randomized prospective clinical study
PubMed ID: 29114862
Adding NB-UVB to FAE sped and increased psoriasis improvement vs FAE alone.
Immune support (6)
- Fumaric acid therapy in psoriasis: a double-blind comparison between fumaric acid compound therapy and monotherapy with dimethylfumaric acid ester
PubMed ID: 2394301
Clinical psoriasis trials with FAEs showed efficacy and reported blood cell changes — indicates immune modulation.
- [Fumaric acid therapy in psoriasis; a double-blind, placebo-controlled study]
PubMed ID: 2263264
Fumarate tablets improved psoriasis and produced reversible lab abnormalities (immune-cell effects).
- Topical calcipotriol plus oral fumaric acid is more effective and faster acting than oral fumaric acid monotherapy in the treatment of severe chronic plaque psoriasis vulgaris
PubMed ID: 12145434
Combination therapy allowed dose-sparing of FAEs while improving PASI — consistent with immune-targeted benefit.
- Efficacy and safety of LAS41008 (dimethyl fumarate) in adults with moderate-to-severe chronic plaque psoriasis: a randomized, double-blind, Fumaderm(®) - and placebo-controlled trial (BRIDGE)
PubMed ID: 27515097
Phase III DMF demonstrated clinical benefit in an immune-mediated disease (psoriasis).
- Influence of medium-chain fatty acids and short-chain organic acids on jejunal morphology and intra-epithelial immune cells in weaned piglets
PubMed ID: 26919402
Piglet study: fumaric+lactic acids increased specific γδ T-cell populations in jejunum (local immune modulation).
- Quality of life outcomes in adults with moderate-to-severe plaque psoriasis treated with dimethylfumarate (DMF): a post hoc analysis of the BRIDGE study
PubMed ID: 31465585
Clinical benefit of DMF in psoriasis implies immunomodulatory activity; DMF is known to affect immune pathways though this trial focused on outcomes rather than mechanistic biomarkers.
Skin repair (5)
- Fumaric acid esters in combination with a 6-week course of narrowband ultraviolet B provides an accelerated response compared with fumaric acid esters monotherapy in patients with moderate-to-severe plaque psoriasis: a randomized prospective clinical study
PubMed ID: 29114862
NB-UVB added to FAEs accelerated psoriasis improvement versus FAEs alone.
- Topical calcipotriol plus oral fumaric acid is more effective and faster acting than oral fumaric acid monotherapy in the treatment of severe chronic plaque psoriasis vulgaris
PubMed ID: 12145434
Addition of topical calcipotriol to FAEs produced faster and greater psoriasis improvement (faster clinical repair).
- Efficacy and safety of fumaric acid esters in young patients aged 10-17 years with moderate-to-severe plaque psoriasis: a randomized, double-blinded, placebo-controlled trial
PubMed ID: 33332574
Pediatric RCT demonstrated faster achievement of PASI75 and PGA improvements versus placebo.
- Dimethyl fumarate is efficacious in severe plaque psoriasis : Post hoc analysis from the BRIDGE trial in Austria
PubMed ID: 31591676
Severe subgroup showed clearer skin and QoL improvement compared with placebo, consistent with accelerated repair.
- Quality of life outcomes in adults with moderate-to-severe plaque psoriasis treated with dimethylfumarate (DMF): a post hoc analysis of the BRIDGE study
PubMed ID: 31465585
Significant improvements in PASI and PGA imply faster clinical skin improvement/repair in many patients treated with DMF.
Mood balance (2)
- Quality of life outcomes in adults with moderate-to-severe plaque psoriasis treated with dimethylfumarate (DMF): a post hoc analysis of the BRIDGE study
PubMed ID: 31465585
DLQI and QoL improved substantially with DMF, indicating better patient‑reported well‑being.
- Efficacy and safety of fumaric acid esters in young patients aged 10-17 years with moderate-to-severe plaque psoriasis: a randomized, double-blinded, placebo-controlled trial
PubMed ID: 33332574
Quality‑of‑life measures improved in pediatric trial alongside skin benefit.
Gut health (2)
- The effect of organic acids on the control of porcine post-weaning diarrhoea
PubMed ID: 11676629
Weaned piglets given organic acids including fumaric acid had reduced diarrhea and improved growth versus untreated controls.
- Effects of dietary combinations of organic acids and medium chain fatty acids on the gastrointestinal microbial ecology and bacterial metabolites in the digestive tract of weaning piglets
PubMed ID: 23798515
Dietary fumaric+lactic acid altered gut bacteria and reduced harmful E. coli markers in piglet colon.
Metabolism (1)
- Disparate effects of adalimumab and fumaric acid esters on cardiovascular risk factors in psoriasis patients: results from a prospective, randomized, observer-blinded head-to-head trial
PubMed ID: 32426884
This trial directly reported reductions in total cholesterol and apolipoprotein B with FAE, demonstrating a measurable metabolic effect.
Similar by evidence
Supplements the same benefits carry qualifying findings for — a fact about the evidence graph, not a recommendation to swap.
Products with Fumaric Acid
Search all22 products whose verified label declares Fumaric Acid — not every bottle that mentions it in a title.